The U.S. Food and Drug Administration recently approved further clinical trials for a type of traditional Chinese medicine for pancreatic cancer treatment, media reported Sunday.
Kanglaite, the anticancer drug, contains ingredients extracted from coix seed, which is an important ingredient in some traditional Chinese medicine.
Li Dapeng, research team leader, said the clinical trial will involve 750 people and cost about $50 million. It will be carried out in China, the U.S. and Europe in the coming three to four years, reported the Xinhua News Agency.
If the drug successfully passes phase III of clinical trials, it is likely to become the first injectible medication involving traditional Chinese medicine to enter the U.S. market.
